Chi Meng Fong
BofA Securities, Research Division

Good morning, everyone. Thanks for joining the BofA Healthcare Conferences. My name is Chi Fong, I have [ Dina Ramadane ] with me today, we are both from the U.S. Bio-pharmaceutical Health Care Team here, Bank of America. I cover Roivant, she covers Immunovant. We are glad to be co-hosting CEO of Roivant, Matthew Gline today. Thanks for joining us, Matt.

Matthew Gline
CEO & Director

I'm so happy to be here. Thank you.

Chi Meng Fong
BofA Securities, Research Division

Okay. Great. Maybe start with some high-level questions, if we may, before we dive into some of the deeper product level questions.

And so as you know, Roivant has gone through several distinct areas, you have the initial [ Myovant days ] through the value realizing exits like TL1A to now you're building franchises like brepo and Immunovant 1402 as multi-indication franchises. So curious, which parts of the original Roivant model have proven durable? And what have you potentially want to move away from us to company matures?

Matthew Gline
CEO & Director

Yes. Look, a great question. Good to be here. Thank you for having me. I can't see that well because the lights are, but I think thanks for being in the room. And thank you for your great coverage of Immunovant.

So Roivant, actually, we celebrated our 12-year anniversary last week. And we've done a lot of things in our history. And I think like it's hard, biotech is such a path-dependent industry. It's hard to say that like any of it was wrong. But we've built